Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.44 |
| ▸ | CCND1 | P24385 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | CYP24A1 | Q07973 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | KLK1 | P06870 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28852853 | 0.88 | HTR2C (0.41) | CDK4CCND1HTR2CP2RX7CNR2 | |
| SCHEMBL281893 | 0.85 | CNR2 (0.49) | CDK4CCND1HTR2CCNR2CNR1 | |
| SCHEMBL849619 | 0.85 | CDK4 (0.43) | CDK4CCND1HTR2CP2RX7CYP24A1 | |
| SCHEMBL30777412 | 0.83 | CDK4 (0.41) | CDK4CCND1HTR2CP2RX7CYP24A1 | |
| SCHEMBL21359752 | 0.83 | CDK4 (0.41) | CDK4CCND1HTR2CP2RX7CYP24A1 | |
| SCHEMBL5794361 | 0.82 | P2RX7 (0.54) | CDK4CCND1HTR2CP2RX7CYP24A1 | |
| SCHEMBL879762 | 0.79 | HTR2C (0.44) | CDK4CCND1HTR2CCNR2 | |
| SCHEMBL851863 | 0.79 | HTR2C (0.41) | CDK4CCND1HTR2CHTR2A | |
| SCHEMBL16302302 | 0.79 | CNR2 (0.39) | CDK4CCND1HTR2CP2RX7CYP24A1 | |
| SCHEMBL24917110 | 0.78 | HTR2C (0.56) | CDK4CCND1HTR2CP2RX7CYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992085-B2 | Octahydro-2H-pyrido[1,2-a]pyrazine compounds | LES LABORATORIES SERVIER (FR) | 2006-01-31 | — | — | US | disclosed |
| CN-1197863-C | NOvel octahydro-2H-pyridino-[1,2-a] pyrazine compound, its prepn. process and medicinal compound contg. them | SERVIER LAB (FR) | 2005-04-20 | — | — | CN | disclosed |
| EP-1275647-B1 | Octahydro-2H-pyrido[1,2-a]pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-11-12 | — | — | EP | disclosed |
| US-20030195216-A1 | Octahydro-2H-pyrido[1,2-a] pyrazine compounds | LES LABORATOIRES SERVIER (FR) | 2003-10-16 | — | — | US | disclosed |
| CN-1397557-A | NOvel octahydro-2H-pyridino-[1,2-a] pyrazine compound, its prepn. process and medicinal compound contg. them | SAVOIREN LAB (FR) | 2003-02-19 | — | — | CN | disclosed |
| EP-1275647-A1 | Octahydro-2H-pyrido[1,2-a]pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195216-A1 | Octahydro-2H-pyrido[1,2-a] pyrazine compounds | CYP2W1, OXER1, IL1R1 | CDK4 3161/4885CCND1 674/4885HTR2C 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.